CADTH Canadian Drug Expert Committee final recommendation : indication: asthma. Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.)

CADTH Canadian Drug Expert Committee final recommendation indication: asthma. Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.)

Bibliographic Details
Main Author: Canadian Agency for Drugs and Technologies in Health (author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Format: eBook
Language:Inglés
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health 2016.
Subjects:
Medical care > Cost effectiveness.
See on Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820285306719
Description
Physical Description:1 online resource (7 pages)

Similar Items